

AD-A160 059 CLONAL ANALYSIS OF HLA-DR AND -DQ ASSOCIATED DETERMINANTS - THEIR CONTRIBUTION TO DW SPECIFICITIES (4). MINNESOTA UNIV. MINNEAPOLIS, N. J. DEGENGAEM, ET AL

CLONAL ANALYSIS OF HLA-DR AND -DQ ASSOCIATED DETERMINANTS - THEIR CONTRIBUTION TO DM SPECIFICITIES
(14) MINNESOTA UNIV MINNEAPOLIS MN J REINSMOEN ET AL

1/1

UNCLASSIFIED 1985 N00014-85-K-0004


1985 N00014-85-K-0004

F/G 6/16

NL

END

FILM ©



MICROCOPY RESOLUTION TEST CHART
NATIONAL BUREAU OF STANDARDS-1963-A

(2)

Abbreviated title: Clonal analysis of HLA-DR and -DQ associated determinants

AD-A160 059

1985

Clonal Analysis of HLA-DR and -DQ Associated
Determinants - Their Contribution to Dw Specificities

Nancy L. Reinsmoen and Fritz H. Bach

This is paper #414 from the Immunobiology Research Center, Departments of Laboratory Medicine/Pathology and Surgery, University of Minnesota, Minneapolis, MN, 55455. This publication was supported by NIH grants AI 17687, AI 18326, and AI 19007, National Multiple Sclerosis Society grant #RG 1505-A-1 and grant ^{N00014-}~~N0014-~~85-K-0004 from the Office of Naval Research.

DTIC FILE COPY

DTIC
ELECTE
OCT 11 1985
S A D

85 10 03 096

This document has been approved
for public release and sale; its
distribution is unlimited.

ABSTRACT

In order to investigate the distribution of epitopes recognized by T cell clones directed against HLA class II products, bulk primed cell populations were generated using cells matched for class I determinants but disparate for class II determinants. Cells were cloned by single cell deposition (FACS IV) or limiting dilution (1 cell/3 wells), and assayed for proliferative and cytolytic function with panels of well-characterized cells. All cytolytic clones generated from an anti-DR4/Dw4/DQw3 priming combination or an anti-DR2/Dw2/DQw1 priming combination lysed essentially all targets sharing the same Dw type as the sensitizing cell. In some cases, other targets were also lysed. For instance, some clones were lytic to targets bearing the same DR antigen but another Dw subtype including a few clones lytic to virtually all cells carrying that DR specificity. An occasional target cell expressing a different DR antigen from the sensitizing cell was also lysed by these clones, in some cases to the same extent of lysis seen on the specific target. Monoclonal antibody inhibition studies identified three groups of clones: the DQ directed clones and clones apparently directed at more than one DR product. However, the number of molecules detected for each haplotype remains to be investigated. Our data indicate that determinants detected on both DR and DQ products are associated with the Dw type of the sensitizing cell showing that there is polymorphism recognized by T cells on both DR and DQ that is subtypic to the serologically defined specificities. Thus, it appears that the bulk T cell response is a composite of individual clones recognizing distinct determinants on these class II molecules. The implications of these findings for studies of HLA restricted recognition are discussed.

ABBREVIATIONS

MLC mixed lymphocyte culture
 HTC homozygous typing cell
 PLT primed lymphocyte test
 IL-2 interleukin-2
 CML cell mediated lympholysis
 EBV Epstein Barr Virus
 mAb monoclonal antibody
 PBL peripheral blood lymphocytes
 LCL lymphoblastoid cell line

| | |
|--------------------|-------------------------------------|
| Accession For | |
| NTIS GRA&I | <input checked="" type="checkbox"/> |
| DTIC TAB | <input type="checkbox"/> |
| Unannounced | <input type="checkbox"/> |
| Justification | <i>per</i> |
| By _____ | |
| Distribution/ | |
| Availability Codes | |
| Dist | Avail and/or Special |
| A-1 | |



INTRODUCTION

The complexity of the HLA-D region has long been recognized based on cellular responses to class II products. Understanding of this region has expanded with study of the protein products and genomic analyses. There appear to be three different families of genes encoding the class II products: DR, DQ (previously referred to as DC, DS, MB, LB-E) and DP (formerly known as SB). The DR family is composed of 3 polymorphic β genes and one relatively invariant α gene. Several, perhaps all, of the serologically defined specificities of DR1 through DRw14 appear to be alleles present on one of the DR $\alpha\beta$ products ($\alpha\beta_1$ by convention) while DRw53 and w52 are probably, at least in some situations, encoded by alleles and present on a DR $\alpha\beta_2$ product. Expression of a third DR $\alpha\beta$ product, and whether the number of DR β products expressed by each haplotype is the same, has not been extensively investigated. The DQ family consists of two α and two β genes with DQw1-3 specificities presumably being encoded by allelic genes. Six specificities have been identified for DP, a family of genes consisting of two α and two β genes. This area has recently been reviewed (1,2).

The cellular methods used to investigate these products are the mixed lymphocyte culture (MLC^{*}) (3-5) utilizing homozygous typing cells (HTCs^{*}) as stimulators (6-9) to define Dw antigenic clusters (10) and the primed lymphocyte culture (PLT^{*}) (11,12) including expansion of these primed cells through cloning methodologies (13). Stimulatory determinants in PLT, which presumably reflect those determinants capable of stimulation in the primary MLC, have been reported as being associated with DR, DQ, DP, (14-34) and the HLA-A,B chromosomal segment (35-39). Dw specificity clusters defined with HTCs are subtypic to the serologically defined DR antigens; for example, several Dw specificities are associated with DR4 (40-42) and DR2 (19,42-48). Dw antigenic clusters (Dw1-19) (10) are not attributable to a single locus,

although the DR product may be immunodominant (20), but rather to the composite responses to stimulation by various stimulatory determinants predominantly associated with class II products. Thus, Dw specificities are "haplotype assignments".

Although there is some evidence that DR and DQ products can stimulate T lymphocytes, it is not clear whether there are determinants associated with both these products that contribute to the Dw haplotype assignment, i.e. have a population distribution corresponding to the subtypic Dw specificity. Our previous studies of class II proteins provided evidence for polymorphism of DR β chains correlating with the Dw subtype of DR4 positive cells (49), a finding which was independently confirmed and extended to DR2 and DQ (50-53). This report provides the first evidence by cellular assays, using panel studies of phenotypically well-characterized cells as well as monoclonal antibody blocking studies, that determinants associated with the DR as well as the DQ product appear to contribute to the definition of a Dw specificity. Thus, the functional polymorphism recognized by T lymphocytes is more extensive than that defined serologically. Further, we show that cloned T cells respond to what are probably two separate DR $\alpha\beta$ dimers, although there is no evidence for a further subtype polymorphism of one of these dimers. To the extent that restricting determinants are Dw subtype associated, as has been recently found (54-56), these data indicate that the restricting determinants could be associated with DR, DQ, or both products.

METHODS

HLA-A, -B, -C, -DR typing

HLA-A, -B, -C typing was performed according to the standard NIH method using approximately 150 antisera. HLA-DR typing for the specificities DR1-8 was performed using a panel of approximately 120 antisera according to the

technique of the 7th International Histocompatibility Workshop (57) on B cells enriched by a nylon wool method (58).

HLA-D typing

HLA-D typing was performed on all cell donors with a panel of approximately 40 homozygous typing cells (HTCs)* representing the specificities Dw1 through 15, LD-5a (44) and FJO (48). MN2 is a previously described HLA-DR2 associated HLA-Dw/LD specificity defined by PLT reagents (43). The MLC technique has been previously described (59-61). Reproducible double normalized relative responses (RR) of 50% or less were considered typing responses.

Target #3 types only as Dw13 by HTCs; however, family studies indicate both haplotypes type as DR4 but only one haplotype carries the Dw13 specificity. Multiple HLA-Dw typings of target #3 and other family members carrying the DR4, Dw blank haplotype demonstrate occasional borderline typing responses to Dw4 HTCs (>40 double normalized relative responses). However, a definite Dw4 assignment could not be given.

Interleukin-2 (IL-2) Production

Peripheral blood lymphocytes were isolated by ficoll-hypaque gradient centrifugation on 10-12 individuals. Cells were pooled, irradiated at 1000 rads, and adjusted to $10 \times 10^6/\text{ml}$. To 75 cm^2 flasks were added 50×10^6 cells, 50 μg indomethacin, 0.5 ml pooled human sera (PHS), and 42.5 ml RPMI-1640. The flasks were incubated 48 hours in a 37°C , 5% CO_2 humidified atmosphere. After centrifugation, the supernatant was decanted and stored at -20°C . Lymphocult-T (Biotest 812,810) was used as the source of IL-2 in the latter experiments.

Priming Cell Combinations

Disparate priming specificities are underscored. A) Anti-DR/Dw4 priming: Responder=HLA-A1,2; B8,w44; DR3,w6;w52; Dw3,6; DQw1,2; DPw1,4. Stimulator=

HLA-A1,2; B8,w44; DR3,4; w52,w53; Dw3,4; DQw2,3; DPw1. B) Anti-DR/Dw2 priming: Responder=HLA-A1,3; B8,7; DR3,8; w52,w53; Dw3,8; DQw2,3; DPw4. Stimulator=HLA-A1,3; B8,7; DR2,3; w52; Dw2,3; DQw1; DPw4,6.

Cloning Techniques

Cloned reagents were generated using a method previously described with some modifications (13). Primed cells cultured for 10 days were stimulated with peripheral blood lymphocytes (PBL*) from the original stimulator (3,000 rad) at a responder:stimulator ratio of 1:3 and recultured for three days. The blasts were separated on a 15-38% percoll gradient (Pharmacia) and plated at a concentration of 1 cell per 3 wells in 72 well histo-plates (006-020-0401 Dynatech Inc. Alexandria, VA) with 1×10^4 feeder cells (lymphoblastoid cell line (LCL*) of the original stimulator cell and cultured in 20% IL-2, 15% PHS, 65% RPMI-1640. Alternatively, blast cells were submitted to single cell deposition utilizing the fluorescence-activated cell sorter (FACS IV - Becton Dickinson, Mountain View, CA). After 10 days those wells with positive growth were transferred to flat bottom wells (Linbro 76-013-05 with 1×10^5 feeder cells and eventually to nickel well plates (Linbro FB-4-TC).

Primed lymphocyte test (PLT*)

The PLT method has been previously described (11, 12, 62). Briefly, cloned cells were added to V bottom plates at a concentration of 10^3 cells per well with 5×10^4 irradiated (3000 rad) stimulator cells. After 40 hours incubation at 37°C in a 5% CO₂ humidified atmosphere, the cultures were labeled for 8 hours with 2 µCi tritiated thymidine (New England Nuclear, Boston, Mass. NEN-0270E, specific activity = 20 Ci/mMol), harvested using a semi-automated cell harvester (SATCH-Knight Inc., Minneapolis, MN) and counted in a LKB 1216 RackBeta β scintillation counter.

Cell Mediated Lympholysis (CML*)

Target Cells: Epstein Barr Virus (EBV*) transformed lymphoblastoid cell lines (LCL) were used as target cells and labeled with 0.25 ml. chromium 51 (.25mCi) for 1 hour; washed 3 times with cold RPMI-1640 containing 20% PHS; and adjusted to 1×10^4 cells ml.

Effectors: The cloned reagent effectors were resuspended in IL-2-free culture medium the day prior to testing. Effectors were adjusted to the appropriate concentrations (50:1, 30:1, 20:1, or 12:1) and 100 λ effectors + 100 λ targets were added to V bottom microtiter plates, spun at 500 rpm for 5 minutes and incubated in a 37° 5% CO₂ humidified environment for 4 hours. The plates were then spun at 1000 rpm for 10 minutes and 150 λ supernatants were aspirated and placed in scintillation vials. Ready-Solv™ HP (Beckman 566436) (2.5 ml.) was added to each vial and the samples were counted in a β scintillation counter. Spontaneous release of ⁵¹Cr was assessed by incubating target cells without effector cells and maximum release of the isotope was assessed by incubating target cells with .1% hexadecyltrimethylammonium bromide. Results were calculated as follows:

$$\text{percent cytotoxicity} = \frac{\text{cpm experimental wells} - \text{cpm spontaneous release}}{\text{cpm maximum release} - \text{cpm spontaneous release}} \times 100$$

The percent standard deviation of all results presented did not exceed 10%.

Monoclonal antibody (mAb*) inhibition studies

The mAb inhibition studies were performed by preincubating the target cells with a final mAb concentration of 1:80, 1:400, or 1:4000 for 30 minutes. The target cells were then added to the effector cells and the technique completed as usual.

Monoclonal antibodies used:

| <u>mAb</u> | <u>Specificity</u> | <u>Contributor</u> | <u>References</u> |
|------------|---------------------|----------------------------------|-------------------|
| L243 | DR monomorphic | American Type Culture Collection | 63 |
| w6/32 | class I | American Type Culture Collection | 64 |
| S3/4 | DQw1 | University of Minnesota | |
| Genox 3.53 | DQw1 | American Type Culture Collection | 65 |
| B7/21 (FA) | DP monomorphic | Trowbridge | 66, 67 |
| Hu-4 | DR monomorphic | Aizawa, Sasazuki | 68, 69, 70 |
| Hu-30 | DR1 and DR2 cells | Aizawa | 68, 69, 70 |
| PL3 | DRw53 | Knowles, Horibe, Dupont | 71 |
| Tu22 | DQ monomorphic + DR | Wernet | 72 |

RESULTS

Utilizing cells from unrelated donors phenotypically identical for HLA-A and B (see Materials and Methods), two bulk primed reagents were generated: one against DR4, DRw53, Dw4, DQw3 disparities and the other against DR2, Dw2, DQw1 disparities. The bulk primed reagents were "cloned" by single cell deposition using the fluorescence activated cell sorter (FACS IV - Becton Dickinson) or by limiting dilution of one cell per three wells. The resulting "clonal" cell populations were expanded in IL-2-containing medium in the presence of x-irradiated feeder cells (lymphoblastoid cell line (LCL) of the original sensitizing cell). After expansion for three weeks, the clones were tested for proliferation in the PLT assay using a panel of well-characterized PBL stimulator cells, and for lytic reactivity in a micro-CML assay using a panel of LCL target cells.

Panel Studies and Monoclonal Antibody Inhibition Studies of Cytolytic Clones Derived from the Anti-DR4, Dw4, DRw53, DQw3 Priming Combination

A total of 55 clones were tested: six clones demonstrated proliferative response to antigen but not cytolytic reactivity, 11 clones were cytolytic but not proliferative, 4 clones demonstrated both proliferative and cytolytic reactivity while 28 clones were nonreactive. Six clones demonstrated very

weak proliferative or cytolytic reactivity and were eliminated from further analysis. Results are presented for all clones which maintained reactivity and could be expanded to the numbers required for these testings.

Table I illustrates the combined results of three CML testings. The disparate priming specificities of the original stimulator cell that are shared by the designated LCL targets are underscored as well as % cytotoxicity values of 10% or greater. The target cell panel included cells which typed for the five HL-A-Dw specificities associated with DR4 (Dw4, Dw10, Dw13, Dw14, and Dw15) as well as DQw3 positive, DR4 negative cells and DQw3 negative, DR4 negative cells. All clones lysed Dw4 positive targets including S (the original stimulator cell). Although target #3 could not be given a definitive assignment of Dw4 (see Materials and Methods), that target was lysed by most but not all clones. Some clones (15, 33, 46, 57) lysed only the Dw4 target cells and target #3; other clones (44, 67, 21, 56, 48, 63) also lysed target cells which typed for other DR4 associated Dw specificities. In addition, certain clones lysed targets which did not type for DR4, Dw4, or DQw3 (targets 13, 14, 15, 17, 18, 22).

Of 10 clones tested in mAb inhibition assays, the cytolytic activity of 9 was inhibited by the DR monomorphic mAb, L243 and Hu-4 (Table II). The anti-DQ mAb, Tu22, also appeared to inhibit cytolysis in some cases by some of the clones; this mAb has been reported to have anti-DR activity (72). The cytolytic activity of clone 21 is not blocked by the anti-DR or -DQ mAb directed at monomorphic determinants at the concentrations shown but is completely blocked (104% inhibition) at a 1:20 dilution of L243 in addition to being significantly inhibited by an anti-DRw53 mAb, PL3. This clone lyses 8 of 8 HLA-DRw53 positive target cells tested as well as 4 targets presumed to be DRw53 positive based on DR and DQ phenotyping (14 to 51% cytotoxicity), but

does not lyse 7 DRw53 negative targets or 3 targets presumed to be DRw53 negative based on DR and DQ phenotyping (Table I) (-20 to 4% cytotoxicity) An intermediate lysis of 9% cytotoxicity was observed with the Dw15 HTC target which does not type as DRw53 with local antisera but does type as DRw53 with 9th International Histocompatibility Workshop antisera.

Panel Studies and Monoclonal Antibody Inhibition Studies of Cytolytic Clones Derived from the Anti-DR2, Dw2, DQw1 Priming Combination

Clones were generated against DR2, Dw2, DQw1 disparate specificities using unrelated cells which typed identically for HLA-A and B and shared the DR3, Dw3, DQw2 and DPw4 specificities. This priming combination was also disparate for DPw6; the 7 DPw6 specific clones generated have, however, been excluded from this analysis. Clones were obtained by single cell deposition (FACS IV) or limiting dilution of one cell per three wells. A total of 123 clones were tested in PLT and CML assays. Twenty-six clones demonstrated proliferative but not cytolytic reactivity; 26 clones were cytolytic but not proliferative; 21 clones demonstrated both functions while 37 were non-reactive. Six additional clones demonstrated very weak and questionable proliferative or cytolytic reactivity and were not included in any of the subsequent experiments. Results are presented for all clones which maintained reactivity and could be expanded to the numbers required for these testings.

Table III illustrates the combined results of three CML testings. All clones tested lysed the Dw2 targets tested. In addition some clones (1-12, 3-84, 3-91) lysed the Dw12 target. Other clones (3-29, 3-27, 1-109) lysed additional DR2 positive targets. Clone 1-17 lysed the Dw2 positive targets as well as the DR2 negative, DQw1 positive targets tested. Clones 3-27 and 1-109 also lysed some DR2 negative, DQw1 negative targets.

Eight clones were tested in monoclonal antibody inhibition assays using anti-DR monomorphic mAb (L243, Hu-4), anti-DQw1 mAb (S3/4, Genox 3:53), anti-"DR2"-mAb (Hu-30), anti-DP mAb (FA), and anti-class I mAb (w6/32) (Table IV). The cytolytic activity of three clones (3-19, 3-29, 3-27) was inhibited by the anti-DR monomorphic mAb L243 and also Hu-4 where tested. The cytolysis of three additional clones (389, 317, 117) was inhibited by the DQw1 mAb.

The cytolytic activity by clones 1-109 was inhibited at the highest concentration of Hu30; 57% inhibition of clone 1-12 was also observed. All mAb tested were used in ascites form except for Hu-30 which was obtained at a 1:10 dilution of the ascites form; thus the final concentrations of Hu-30 mAb tested were 1:800, 1:4,000 and 1:40,000. Hu-4 did not inhibit the cytolysis of these two clones while there was slight inhibition demonstrated by L243 at the concentration shown.

Table V demonstrates the patterns of target cell lysis by the 3 DR-directed and 3 DQ-directed clones. Clone 3-19 lysed only Dw2 positive targets while clone 3-29 lysed all DR2 positive targets and clone 3-27 lysed some additional DR2 negative targets. Two of the DQ directed clones (3-89 and 3-17) lysed only Dw2 positive targets while clone 1-17 also lysed two additional DQw1 positive cells (targets 7 and 8).

Panel Studies of Proliferative Clones Derived from Both Priming Cell Combinations

The PLT testings of representative proliferative clones are illustrated in Tables VI and VII. Some clones (16, 56, 63) were restimulated by some DR4 positive cells and not by DR4 negative cells tested to date. Other clones (40, 41) were restimulated by some DR4 positive cells as well as some DQw3 positive cells. Clone 16 was restimulated by all DR4 positive cells tested. However, no clones were restimulated exclusively by Dw4 positive cells. Likewise, as illustrated in Table VII, no clones were exclusively restimulated

by Dw2 positive cells. Other clones (1-101, 1-84, 3-22, 3-29, 1-109) were restimulated by several DR2 positive cells. Three clones (3-22, 3-29, 1-109) were also restimulated by a DR2 negative, DQw1 negative cell (#15).

PLT reagents were generated by plating 5 cells per well; these reagents may not be true clones but are derived from a limited number of primed cells. When these reagents were screened for proliferative reactivity (Table VIII), several, as represented by reagents 596, 5178, 5186, and 5210, were restimulated by the Dw2 positive cells with clear discrimination from other DR2 positive or DR2 negative cells.

DISCUSSION

The definition of specificities recognized by T lymphocytes has relied largely on the proliferative response to class II MHC products in the mixed lymphocyte culture assay. The primary MLC has used HTC's as stimulators to define Dw specificities; the secondary MLC, i.e. the PLT assay, has yielded a better understanding of the individual stimulatory components, especially with cloning of the PLT-reactive cells.

We were prompted to investigate individual allodeterminants associated with DR and DQ with cloned T cells with two interrelated questions in mind. First, to establish which class II dimers express polymorphisms associated with the Dw subtypes and thus provide direct evidence for individual class II products regarding the existence of the more extensive polymorphisms recognized by T lymphocytes as compared with the serologically defined DR and DQ segregant series. Second, based on studies in mouse demonstrating that the various class II products may function differentially in regulating immune response (in that I-A restricts recognition of the beta subunit of lactate dehydrogenase for T helper cells and I-E for T suppressor cells (73-75)) to establish the basis for the probing of similar questions in man. The

investigation of allodeterminants is relevant in this regard; we have performed/participated in several studies recently that demonstrate that restricting determinants for several different nominal antigens are subtypic to the serologically defined DR and DQ specificities and may be closely related to the Dw associated allodeterminants (54-56). A detailed dissection of allodeterminants recognized by T lymphocytes is thus essential for any such undertaking.

Bulk primed cell populations were generated using cells matched for class I determinants and disparate for class II determinants. The primed cells were cloned by single cell deposition (FACS IV) or limiting dilution (1 cell/3 wells), and assayed for proliferative and cytolytic function with panels of cells well-characterized for HLA. The results suggest that there are multiple stimulatory determinants on the DR and DQ molecules; many of these determinants are commonly shared with cells which type for the same HLA-Dw specificity as the original sensitizing cell. In addition, these determinants may be occasionally shared by, or highly cross-reactive with, cells which do not express the same Dw, DR or DQ specificities as the sensitizing cell.

Cytolytic clones generated from the anti-DR4/Dw4 priming combination (Table I) or the anti-DR2/Dw2 priming combination (Table III), in general, lysed targets sharing the same Dw type as the sensitizing cell, with some clones lysing additional target cells. Whether the clones which only lyse targets bearing the same Dw specificity as the sensitizing cell are all directed against a single determinant or whether several determinants are frequently found on cells of that Dw type remains to be elucidated.

Monoclonal antibody inhibition studies of those clones directed at "DR" identified most clones derived from the anti-DR4/Dw4/DQw3 priming combination

which were blocked by the mAb directed at DR monomorphic determinants but not by the anti-DRw53 mAb, PL3. One clone (#21) appeared to be directed at a determinant associated or identical with DRw53 in that it lysed 8 of 8 DRw53 positive targets and was inhibited by the mAb PL3, described by Horibe et al. (71). Knowles et al.¹ have performed biochemical analysis of the DRw53 determinant defined by PL3 and have demonstrated that this determinant is carried on a single beta chain which appears to be identical to the previously described BR molecule (76). They found that this beta chain migrates identically in isoelectric focusing (IEF) techniques for all DR4 positive cells regardless of their Dw assignment by HTC typing. In contrast, the other DR beta chains show considerable heterogeneity in their isoelectric points, as we initially showed for DR β chain heterogeneity in IEF correlating with DR4 associated Dw subtypes (49). Based on their results and our own panel studies we believe that the reactivity of clone #21 is probably directed against a different DR $\alpha\beta$ dimer (referred to as DR $\alpha\beta_2$ (77)) than that recognized by the majority of clones that are strongly blocked by the anti-DR monomorphic mAb (presumably DR β_1) and not blocked by PL3.

No apparent DQ directed clones were detected from the clones generated in this priming cell combination, although the responder and sensitizing cells were disparate for the DQw3 specificity. Fewer clones were initially tested from this priming combination than for the anti-DR2/Dw2/DQw1 priming combination (55 versus 112 respectively) where DQ directed clones were observed; DQ directed clones may have been detected in this priming combination had more clones been expanded to the quantities needed for testing. These findings are consistent with our previous suggestion that in

¹Knowles, R.W., Flomenberg, N., Horibe, K., Winchester, R., Radka, S.F. and Dupont, B., manuscript submitted.

some combinations DR associated determinants may be immunodominant (20).

Some clones from the anti-DR2/Dw2/DQw1 priming combination appeared to be DR directed while others appeared to be DQ directed based on blocking of cytolytic reactivity with mAb. Certain of the DR directed as well as the DQ directed groups of clones lysed only target cells bearing the same Dw specificity as the sensitizing cell. These results demonstrate that some clones directed against the DR or DQ molecules recognize determinants that are associated with the same Dw specificity as the sensitizing cell. Thus, it appears that determinants on both the DR (presumably DR $\alpha\beta$ 1) and DQ molecules contribute to the definition of a Dw subtype specificity assignment for a given cell. Neither the existence of Dw subtypes (given the complexity of determinants that make up Dw and the rather loose definition of a Dw specificity) nor the protein polymorphism discussed above, allows strict interpretation with regard to polymorphism of individual products of DR or DQ as seen by T lymphocytes. The question, thus, arises as to the extent of polymorphism detected by T lymphocytes associated with a single class II product that is subtypic to one or more serologically defined specificities of that product. Our demonstration in this study of subtypic determinants of DR and DQ with cloned T cells allows more rigorous interpretation. It would appear that there is a subtype polymorphism in at least some haplotypes for DR $\alpha\beta$ 1 and DQ defined by T lymphocytes as compared with the serologically defined polymorphism. We have recently speculated on the evolutionary aspects of these polymorphisms based on attempts to find restriction fragment length polymorphisms associated with the Dw subtypes (1,78).

Other clones appeared to recognize determinants on DR molecules from cells which typed for the same DR, but different Dw, specificities; occasionally a target cell which did not bear the same DR type as the

sensitizing cell was lysed to as great a degree as the sensitizing cell. These results indicate that clones are recognizing several different determinants on the DR molecules, some of which may be shared or highly crossreactive with determinants on DR molecules from cells of a different DR type.

The cytolytic activity of two clones (1-12, 1-109) obtained from the anti-DR2/Dw2/DQw1 priming combination was not blocked by the anti-DR monomorphic, -DQ, -DP, or -class I mAb. Cytolysis by one of these clones (1-109) was, and by a second clone (1-12) may have been blocked by the mAb, Hu-30. HU-30 did not block reactivity of a clone (3-27) that was blocked by L243 (DR monomorphic mAb). Certainly L243 or Hu-4 may bind to a different part of the same molecule to which Hu-30 also binds, such that recognition of either determinant is not interfered with by the binding of the other mAb. However, an equally plausible interpretation of these results is that Hu-30 may detect a DR molecule distinct from the DR molecule presumably expressing the DR1-14 alleles (1).

The mAb Hu-30 was initially defined as detecting a polymorphic determinant common to DR1 and DR2 positive cells (68) and has recently been described by Nishimura et al. (69) and Sone et al. (70) to detect a DR product common to Dw2 and Dw12 positive cells which they interpreted to be the DR β chain expressing DR2. They identified another DR product different between Dw2 and Dw12 positive cells which they designated as a novel class II molecule. We believe our results, and theirs as well, are consistent with an alternate interpretation. The DR product detected by Hu-30 and shared by Dw2 and Dw12 cells may be encoded by the "allele" of DRw52 and DRw53, i.e. a specificity which might be called DRw51, which has been previously undefined for DR2 and DR1 positive cells.

In addition, these clones may also be informative to classify cells which cannot be assuredly assigned to a Dw specificity by conventional HTC typing. Target cell #3 (Table III) was lysed by 10 of 14 anti-DR4-Dw4 clones and thus is the most frequently lysed target besides the known Dw4 positive target cells in these experiments. Family studies indicate target cell #3 is DR4 homozygous but heterozygous Dw13, Dw blank. This cell, as well as other family members' cells carrying the DR4, Dw blank haplotype occasionally give double normalized relative responses of 40-50% to stimulation by Dw4 HTCs but not other DR4 HTCs. This cell may carry a DR molecule which is similar to the conventional DR4 molecule contributing to the Dw4 phenotype yet does not share some of the other determinants commonly found with Dw4. Thus, there may be cells for which the Dw type may never be assigned by HTC typing (i.e. Dw blank assignment) but testing with PLT clones will help define specific class II products of that haplotype.

The proliferative clones (Tables VI and VII), like the cytolytic clones, were, for the most part, restimulated by cells which type for the same Dw specificity as the sensitizing cell. Although most clones were not restimulated exclusively by cells with the same Dw type as the sensitizing cell, reagents generated from plating five cells per well frequently demonstrated strong proliferative reactivity associated with restimulation by cells with the same Dw specificity, e.g. by Dw2 positive cells with clear discrimination from other DR2 positive or DR2 negative cells (Table VIII). These reagents are presumably composed of clones that are, in part, directed against different determinants on the DR molecule. If each determinant is common to the Dw2 cells but only occasionally found on other cells, and the various determinants are found on different non-Dw2 cells, the Dw2 positive cells would restimulate each clone comprising the 5 cell/well reagent

resulting in strong proliferation. If a Dw2 negative cell also carried an epitope detected by one of the clones in the reagent, the restimulation of one of potentially five clones would be observed as much weaker restimulation easily distinguished from restimulation by the Dw2 cells. Such reagents started from 5 cell/well may thus be potentially better typing reagents for the Dw specificities, but less useful for understanding the individual determinants involved.

We accept as a working model that the extensive polymorphism for DR (DR1 through DRw14) is associated with an $\alpha\beta 1$ dimer and DRw53 with $\alpha\beta 2$. We would suggest that much, or perhaps essentially all, of the polymorphism seen by clones blocked with L243 and Hu4 may be also associated with $\alpha\beta 1$ for both DR4 and DR2. In fact, although we have only two clones putatively reactive with a determinant associated with DRw53 for DR4 haplotypes (blocked by PL3) and with the potential DR $\alpha\beta 2$ dimer of DR2 haplotypes (blocked by Hu30), these clones do not detect a polymorphism subtypic to the DR specificity of the $\alpha\beta 2$ dimer (DRw53 and the presumed "DRw51"). There is increasing, albeit limited, evidence supporting the concept that the DR $\beta 2$ gene/protein is relatively conserved on haplotypes carrying a single serologically defined specificity such as DR4 or DR2. First, several investigators have found one DR β spot in IEF that is relatively constant within the subtypes of DR2 (68) and DR4² (79); in the terminology we are using, this would be the DR $\beta 2$ protein. Second, the two clones (21 and 1-109) described in the present study as potentially reactive with a DR $\alpha\beta 2$ dimer both react with essentially all the DR4 and DR2 positive cells, respectively (although one clone that may be blocked by Hu30 reacts only with Dw2 positive cells).

²Knowles, R.W., Flomenberg, N., Horibe, K., Winchester, R., Radka, S.F. and Dupont, B., manuscript submitted.

Thus, it may be that the more extensive T lymphocyte recognized polymorphism is associated primarily with DR α β 1 and DQ and that DR α β 2 is relatively conserved.

REFERENCES

1. Bach FH: The HLA class II genes and products: the HLA-D region. *Immunol Today* 6:89-94, 1985.
2. Shackelford DA, Kaufman JK, Korman AJ, Strominger JL. HLA-DR antigens: structure, separation of subpopulations, gene cloning, and function. *Immunol Rev* 66:133, 1982.
3. Bain B, Vas R, Lowenstein L: The development of large immature cells in mixed leukocyte culture. *Blood* 23:108, 1964.
4. Bach FH, Hirschorn K: Lymphocyte interaction: A potential histocompatibility test in vitro. *Science* 143:813, 1964.
5. Bach FH, Voynow NK: One-way stimulation in mixed leukocyte cultures. *Science* 153:545, 1966.
6. Mempel W, Grosse-Wilde H, Baumann P, Netzel B, Steinbauer-Rosenthal I, Scholz S, Bertrams J, Albert, ED: Population genetics of the MLC response: Typing for MLC determinants using homozygous and heterozygous reference cells. *Transplant Proc* 5:1529, 1973.
7. Jorgensen F, Lamm LU, Kissmeyer-Nielsen F: Mixed lymphocyte cultures with inbred individuals. *Tissue Antigens* 3:323, 1973.
8. van den Tweel JG, Blusse van Oud Alblas A, Keuning JJ, Goulmy E, Termijtelen A, Bach ML, van Rood JJ: Typing for MLC (LD). I. lymphocyte from cousin-marriage offspring as typing cells. *Transplant Proc* 5:1534, 1973.
9. Dupont B, Gersild C, Jansen GS, Nielsen LS, Thonsen M, Svejgaard A: Typing for MLC determinants by means of LD-homozygous and LD-heterozygous test cells. *Transplant Proc* 4:1543, 1973.
10. Grosse-Wilde H, Doxiadia I, Brandt H: Joint Report Cellular Part (HTC), 9th International Histocompatibility Workshop, In: ED Albert, MP Baur, WR Mayr, Eds. *Histocompatibility Testing 1984*, Springer-Verlag, in press.

11. Sheehy MJ, Sondel PM, Bach ML, Wank R, Bach FH: HL-A LD (lymphocyte defined) typing: A rapid assay with primed lymphocytes. *Science* 188:1308, 1975.
12. Sheehy MJ, Bach FH: Primed LD typing (PLT)--Technical considerations. *Tissue Antigens* 8:157, 1976.
13. Bach FH, Inouye H, Hank JA, Alter BJ: Human T lymphocyte clones reactive in primed lymphocyte typing and cytotoxicity. *Nature* 281:307, 1979.
14. Fradelizi D, Nunez-Roldan A, Sasportes M: Human Ia-like DRw lymphocyte antigens stimulating activity in primary mixed lymphocyte reaction. *Eur J Immunol* 8:88, 1978.
15. DeWolf WC, Carroll PG, Mehta CK, Martin SL, Yunis EJ: The genetics of PLT response. II. HLA-DRw is a major PLT-stimulating determinant. *J Immunol* 123:37, 1979.
16. Morling N, Jakobsen BK, Platz P, Ryder LP, Svejgaard A, Thomsen M: A "new" primed lymphocyte typing (PLT) defined DP-antigen associated with a private HLA-DR antigen. *Tissue Antigens* 16:95, 1980.
17. Suciu-Foca N, Susinno E, McKiernan P, Rohowsky C, Weiner J, Rubinstein, P: DRw determinants on human T cells primed against allogeneic lymphocytes. *Transplant Proc* 10:845, 1978.
18. Hartzmann RJ, Pappas F, Romano PJ, Johnson AH, Ward FE, Amos DB: Dissociation of HLA-D and HLA-DR using primed LD typing. *Transplant Proc* 10:809, 1978.

19. Reinsmoen NL, Noreen HJ, Sasazuki T, Segall M, Bach FH: Roles of HLA-DR and HLA-D antigens in haplotype-primed LD typing reagents. Proceedings of the 13th International Leukocyte Culture Conference. In: The Molecular Basis of Immune Cell Function. Amsterdam, Elsevier North Holland. p. 529, 1979.
20. Bach FH, Reinsmoen N, Segall M: Definition of HLA antigens with cellular reactants. Transplant Proc 15:102, 1983.
21. Zeevi A, Scheffel C, Annen K, Bass G, Marrari M, Duquesnoy RJ: Association of PLT specificity of alloreactive lymphocyte clones with HLA-DR, MB and MT determinants. Immunogenetics 16:209, 1982.
22. Duquesnoy RJ, Zeevi A, Marrari M, Halim K: Immunogenetic analysis of the HLA-D region: Serological and cellular detection of the MB system. Clin Immunol Immunopathol 23:254, 1982.
23. Mawas C, Charmot D, Mercier P: Split of HLA-D into two regions α and β by a recombination between HLA-D and GLO. I. Study in a family and primed lymphocyte typing for determinants coded by the β region. Tissue Antigens 15:458, 1980.
24. Shaw S, Johnson AH, Shearer GM: Evidence for a new segregant series of B cell antigens that are encoded in the HLA-D region and that stimulate secondary allogeneic proliferative and cytotoxic responses. J Exp Med 152:565, 1980.
25. Nunez-Roldan A, Sasportes M, Fradelizi D: Analysis of products involved in primary and secondary allogeneic proliferation in man. II. Detection secondary allogeneic proliferation in man. II. Detection of products different from Ia-like, DRw antigens, activating secondary allogeneic proliferation in man. Immunogenetics 6:43 1978.

26. Termijtelen A, Bradley BA, van Rood JJ: A new determinant, defined by PLT, coded for in the HLA region and apparently independent of the HLA-D and DR loci. *Tissue Antigens* 15:267, 1980.
27. Sasportes M, Nunez-Roldan A, Fradelizi D: Analysis of products involved in primary and secondary allogeneic proliferation in man. III. Further evidence for products different for Ia-like DRw antigens, activating secondary allogenic proliferation in man. *Immunogenetics* 6:55, 1978.
28. Wank R, Schendel DJ, Hansen JA, Dupont B: The lymphocyte restimulation system: Evaluation by intra-HLA-D group priming. *Immunogenetics* 6:107, 1978.
29. Segall M, Reinsmoen NL, Noreen HJ, Bach FH: Complexity of the HLA-D region studied by primed lymphocyte test. *J. Exp. Med.* 152:156s, 1980.
30. Shaw S, Kavathas P, Pollack MS, Charmot D, Mawas C: Family studies define a new histocompatibility locus, SB, between HLA-DR and GLO. *Nature (Lond.)* 293:745, 1981.
31. Reinsmoen NL, Bach FH: HLA-D region complexity associated with HLA-DR Dw and SB phenotypes. *Transplant Proc* 15:76, 1983.
32. Pawelec G, Shaw S, Schneider M, Blaurech M, Frauer M, Brackerts D, Wernet P: Population studies of the HLA-linked SB antigen and their relative importance in primary MLC-typing analysis of HLA-D homozygous typing cells and normal heterozygous populations. *Hum Immunol* 5:215, 1982.
33. Termijtelen A, van Rood JJ: The role in primary MLC of the non HLA-D/DR determinant PL3A. *Tissue Antigens* 17:57, 1981.
34. Shaw S, Charmot D: The genetics of cellular recognition of HLA-D region products. Meeting Summary, Marseille. *Hum Immunol* 8:1, 1982.

35. Johnson AH, Amos DB, Noreen H, Yunis EJ: Strong mixed lymphocyte reaction associated with the LA or first locus HL-A. *Transplantation* 20:291, 1975.
36. Zeevi A, Duquesnoy RJ: PLT specificity of alloreactive lymphocyte clones for HLA-B locus determinants. *Proc Natl Acad Sci* 80:1440, 1983.
37. Wank R, Schendel DJ, Hansen JA, Yunis EJ, Dupont B: Two different HLA restimulating determinants separated by recombination and titration. *Transplant Proc* 9:1771, 1977.
38. Reinsmoen NL, Anichini A, Bach FH: Clonal analysis of T lymphocyte response to an isolated class I disparity. *Hum Immunol* 8:195, 1983.
39. Flomenberg N, Naito K, Duffy E, Knowles RW, Evans RL, Dupont B: Alloctotoxic T-cell clones: both leu 2+3-and 2-3+ T cells recognize class I histocompatibility antigens. *Eur J Immunol* 13(11):905, 1983.
40. Reinsmoen NL, Bach FH: Five HLA-D clusters associated with HLA-DR. *Hum Immunol* 4:249, 1982.
41. Nose Y, Sato K, Nakagawa M, Kondok K, Inouye H, Tsuji K: HLA-D clusters associated with DR4 in the Japanese population. *Hum Immunol* 5:199, 1982.
42. Mickelson E, Brautbar C, Misperos B, Cohen N, Amar A, Kim S, Lanier A, Hansen JA: HLA-DR2 and DR4 further defined by two new HLA-D specificities (HTC) derived from Israeli Jewish donors: comparative study in Caucasian, Korean, Eskimo and Israeli populations. *Tissue Antigens* 24:197, 1984.
43. Reinsmoen NL, Layrisse Z, Betuel H, Bach FH. A study of HLA-DR2 associated HLA-Dw/LD specificities. *Hum Immunol* 11:105, 1984.

44. Layrisse Z, Simoney N, Park MS, Terasaki PI. HLA-D and DRw determinants in an American Indigenous Isolate. *Transplant Proc* 11:1788, 1979.
45. Richiardi P, Belvidere M, Borelli I, DeMarchi M, Curtine EM: Split of HLA-D and DRw2 into subtypic specificities closely correlated to two HLA-D products. *Immunogenetics* 7:57, 1978.
46. DeMarchi M, Varetto O, Savina C, Borelli I, Curtoni ES, Carbonara AO: Relationships between HLA-D and DR. In: PI Terasaki, *Histocompatibility Testing 1980*. Los Angeles, University of California, 1980, p. 893.
47. Cohen N, Amar A, Oksenberg J, Brautbar C: HLA-D clusters associated with DR2 and the definition of HLA-D"AZH," a new DR2 related HLA-D specificity in Israel. *Tissue Antigens* 24:1, 1984.
48. Freidel AC, Betuel H, Gebuhrer L, Farre A, Lambert J: Distinct subtypes of HLA-D associated with DR2. In: *Histocompatibility Testing 1984* (Eds: ED Albert, MO Baur, WR Mayr) Springer Verlag, New York, in press.
49. Groner J, Watson A, Bach FH: Dw/LD related molecular polymorphism of DR4 beta chains. *J Exp Med* 157:1687, 1983.
50. Nepom BS, Nepom GT, Mickelson E, Antonelli P, Hansen JA: Electrophoretic analysis of human HLA-DR antigens from HLA-DR antigens from HLA-DR4 homozygous cell lines: Correlation between β -chain diversity and HLA-D. *Proc Natl Acad Sci USA* 80:6962, 1983.
51. Nepom GT, Nepom BS, Antonelli P, Mickelson E, Silver J, Goyert SM, Hansen JA: The HLA-DR4 family of haplotypes consists of a series of distinct DR and DS molecules. *J Exp Med* 159:394, 1984.

52. Nepom GT, Nepom GS, Thelsson ME, Mickelson E, Antonelli P, Hansen JA:
Multiple Ia-like molecules characterize HLA-DR2-associated haplotypes
which differ in HLA-D. Hum Immunol 10:153, 1984.
53. Groner JP, Bach, FH: DQw1 β chain molecular polymorphism associated with
LD/Dw subtypes of DR2. In: Histocompatibility Testing 1984. (Eds.:
E.D. Albert, M.P. Baur, W.R. Mayr) Springer-Verlag, New York in press,
1984.
54. Quigstad E, Thorsby E, Reinsmoen NL, Bach FH: Close association between
the Dw14 (LD40) subtype of HLA-DR4 and a restriction element for
antigen-specific T cell clones. Immunogenetics, in press.
55. Reinsmoen NL, Volkman DJ, Bach FH, Fauci AS: Soluble antigen specific
recognition of the DR4/LD40 determinant by human T cell clones producing
multiple lymphokines. Federation Proc 43:1819, 1984.
56. Linner KM, Monroy C, Bach FH, Gehrz RC: Dw subtypes of
serologically defined DR-DQ specificities restrict recognition of
cytomegalovirus. Submitted for publication.
57. Bodmer JG, Pickbourne P, Richards S: Joint report Ia serology. In:
Histocompatibility Testing 1977. (Ed.: W.R. Bodmer) Copenhagen,
Munksgaard, p. 35, 1977.
58. Danilovs, JA, Ayoub G, Terasaki P: B lymphocyte isolation by
thrombin-nylon wool. In: Histocompatibility Testing 1980. (Ed.: P.I.
Terasaki) Los Angeles, University of California, p. 287, 1980.
59. Hartzman RJ, Segall M, Bach ML, Bach FH: Histocompatibility matching.
VI. Miniaturization of the mixed leukocyte culture test: A preliminary
report. Transplantation 11:268. 1971.

60. O'Leary J, Reinsmoen NL, Yunis EJ: Mixed lymphocyte reaction. In: Manual of Clinical Immunology. Washington, D.C., American Society for Microbiology, p. 820, 1976.
61. Reinsmoen NL, Bach FH: Cellular typing: HTC-PLT (D, DR, SB). In: Cellular Immunology 1983, (Ed.: Eugene Heisse) AACHT, NY, NY, p. 66, 1983.
62. Reinsmoen N, Segall M: Primed LD (lymphocyte) typing (PLT). American Association for Clinical Histocompatibility Testing Technical Manual. New York, AACHT, p. IV:3, 1981.
63. Lampson LA, Levy R: Two populations of Ia-like molecules on a human β cell line. J Immunol 125:293, 1980.
64. Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, Ziegler A: Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis. Cell 14:9, 1978.
65. Brodsky FM, Parham P, Bodmer WF: Monoclonal antibodies to HLA-DRw determinants. Tissue Antigens 16:30, 1980.
66. Royston I, Omary MB, Trowbridge IS: Monoclonal antibodies to a human T-cell antigen and Ia-like antigen in the characterization of lymphoid leukemia. Transplant Proc 13:761, 1981.
67. Watson AJ, DeMars R, Trowbridge IS, Bach FH: Detection of a novel human class II HLA antigen. Nature (Lond.) 304:358, 1983.
68. Kasahara M, Ogasawara K, Ikeda H, Okuyama T, Ishikawa N, Takenouchi T, Wakisaka A, Kikuchi Y, Aizawa M: A monoclonal antibody that detects a polymorphic determinant common to HLA-DR1 and 2. Tissue Antigens 21:105, 1983.

69. Nishimura Y, Tsukamoto K, Sone T, Hirayama K, Takenouchi T, Ogasawara K, Kasahara M, Wakisaka A, Aizawa M, Sasazuki T: Molecular and functional analysis of class II molecules characteristic to HLA-Dw2 and Dw12. In: Histocompatibility Testing 1984. (Eds.: E.D. Albert, M.P. Baur, W.R. Mayr) Springer-Verlag, New York, p. 504.
70. Sone T, Tsukamoto K, Hirayama K, Nishimura Y, Takenouchi T, Aizawa M, Sasazuki T: A novel class II molecule responsible for the primary MLR between HLA-Dwa and Dw12. J Immunol, In press.
71. Horibe K, Flomenberg N, Pollack MS, Adams TE, Dupont B, Knowles RW: Biochemical and functional evidence that an MT3 supertypic determinant defined by a monoclonal antibody is carried on the DR molecule on HLA-DR7 cell lines. J Immunol 133:3195, 1984.
72. Pawelec GP, Shaw S, Ziegler A, Muller C, Wernet P: Differential inhibition of HLA-D or SB-directed secondary lymphoproliferative responses with monoclonal antibodies detecting human Ia-like determinants. J Immunol 129:1070, 1982.
73. Baxevasis CN, Ishii N, Nagy ZA, Klein J: Role of the E^k molecule in the generation of suppressor T cells in response to LDH_B. Scand J Immunol 16:25, 1982.
74. Baxevasis CN, Ishii N, Nagy ZA, Klein J: H-2 controlled suppression of T cell response to lactate dehydrogenase B. J Exp Med 156:882, 1982.
75. Baxevasis CN, Nagy ZA, Klein J: The nature of the interaction between suppressor and helper T cells in the response to LDH_B. J Immunol 131:628, 1983.
76. Tanigaki N, Tosi R, Duquesnoy RJ, Ferrara GB: Three Ia species with different structures and alloantigenic determinants in an HLA-homozygous cell line. J Exp Med 157:231, 1983.

77. Hurley CK, Giles RC, Nunez G, DeMars R, Nadler L, Winchester R, Stastny P, Capra JD: Molecular localization of human class II MT2 and MT3 determinant. J Exp Med 160:472, 1984.
78. Nicklas JN, Noreen HN, Segall M, Bach FH: Southern analysis of DNA polymorphism between Dw subtypes of DR4. Hum Immunol, in press, 1984.
79. Suzuki M., Maeda H., Mukai R, Yabe T, Hamaguchi H: Identification of the MT3 molecule using two-dimensional gel electrophoresis and alloantisera. Immunogenetics 18:575, 1983.

ACKNOWLEDGMENTS

The authors would like to thank Drs. Knowles, Dupont, Sasazuki, and Aizawa for contributing monoclonal antibodies; Martin Banas, Kim Butters, Mike Diko, Linda Edwins, Donna Kittleson, Barry Leece, Alina Negus and Joan Shaughnessy for technical assistance; and Nancy Andresen and Connie Greenberg for preparation of manuscript.

TABLE I

Cytolytic Clones - Anti DR/Dw4 Priming*
Targets

| | S1 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
|---------|-----|------|------|------|-------|-------|-------|-------|-------|-------|-------|-----|
| DR | 3,4 | 4,4 | 4,4 | 4,4 | 4,4 | 4,4 | 4,4 | 4,4 | 4,4 | 4,4 | 4,4 | |
| DRw | 53 | (53) | (53) | 53 | (53) | (53) | 53 | 53 | - | 53 | 53 | |
| Dw | 3,4 | 4,4 | 4,4 | 13,4 | 13,13 | 13,13 | 14,14 | 14,14 | 15,15 | 10,10 | 10,10 | |
| DQ | 3 | 3 | 3 | (3) | (3) | 3 | 3 | 3 | - | 3 | 3 | |
| DP | 1 | 4 | 3,4 | NT | NT | 5 | 2,3 | 3,6 | 5 | NT | 4 | |
| clone # | | | | | | | | | | | | |
| 15 | 18 | 34 | 25 | 15 | 3 | 1 | -2 | -19 | 2 | -2 | 3 | |
| 33 | 43 | 62 | 46 | 34 | 1 | 8 | 8 | -10 | 2 | -4 | 1 | |
| 46 | 16 | 62 | 37 | 28 | 9 | 3 | 5 | -7 | 8 | 10 | 7 | |
| 57 | 37 | 57 | 25 | 27 | 2 | 5 | 2 | -13 | 3 | 1 | 3 | |
| 9 | 13 | 56 | 17 | -2 | -4 | -8 | 1 | NT | -4 | -3 | 4 | |
| 44 | 9 | 56 | 16 | -1 | -2 | -5 | -1 | NT | 4 | -1 | 5 | |
| 45 | 11 | 56 | 39 | 1 | -1 | -3 | 12 | NT | 21 | -2 | 2 | |
| 12 | 55 | 65 | 60 | 37 | 6 | 0 | 3 | -18 | 6 | -4 | 5 | |
| 67 | 35 | 59 | 44 | 46 | -1 | 43 | -1 | -19 | 3 | 1 | 68 | |
| 37 | 21 | 86 | 58 | 16 | -2 | 5 | 16 | NT | 3 | -6 | 1 | |
| 21 | 14 | 46 | 24 | 22 | 17 | 14 | 26 | 17 | 9 | 17 | 71 | |
| 56 | 31 | 64 | 35 | 32 | 62 | 24 | 55 | NT | 25 | -4 | 3 | |
| 48 | 14 | 46 | 25 | 27 | 34 | 5 | 62 | 64 | 19 | 10 | 3 | |
| 63 | 34 | 70 | 42 | 11 | 50 | 53 | 32 | NT | 16 | 22 | 67 | |
| Targets | | | | | | | | | | | | |
| | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| DR | 5,5 | 5,5 | 3,3 | 2,2 | 1,9 | 2,6 | 2,2 | 1,1 | 2,3 | 3,3 | 6,6 | 7,7 |
| 52 | NT | NT | 52 | NT | 53 | 52 | - | - | 52 | NT | 52 | 53 |
| Dw | 5,5 | 5,5 | 3,3 | 2,2 | 1,BSK | 6,MN2 | 2,2 | 1,1 | 2,3 | 3,3 | 6,6 | 7,7 |
| DQ | 3 | NT | 2 | NT | 1 | 1 | 1 | 1 | 1 | NT | 1 | 2 |
| DP | 4 | 4 | 3,4 | 4,5 | NT | NT | 2,5 | 3,4 | 4,6 | 1,3 | 2,4 | 4 |
| clone # | | | | | | | | | | | | |
| 15 | -5 | -4 | 6 | 1 | 3 | -4 | -2 | -5 | -5 | -18 | -9 | -7 |
| 33 | -6 | -7 | 2 | -2 | 4 | -6 | -6 | 3 | -4 | -2 | -3 | -4 |
| 46 | -7 | -7 | 4 | -1 | 3 | -5 | -4 | -2 | 4 | -8 | 5 | -8 |
| 57 | -5 | -4 | 3 | -1 | 5 | -5 | -4 | -1 | 3 | -10 | 1 | 1 |
| 9 | NT | NT | NT | NT | NT | NT | NT | NT | -3 | NT | NT | NT |
| 44 | -6 | -5 | 17 | 18 | 36 | -5 | -1 | 16 | -4 | -20 | -7 | -6 |
| 45 | -5 | -4 | 29 | 24 | 21 | -3 | -3 | -3 | 2 | -17 | -8 | -9 |
| 12 | -4 | -5 | 16 | 10 | 8 | -4 | -1 | -7 | 1 | -16 | -6 | -9 |
| 67 | 2 | 6 | 10 | NT | NT | -2 | 16 | 2 | 7 | -4 | -2 | -1 |
| 37 | -4 | 4 | 17 | 6 | 13 | -4 | -1 | -5 | -4 | -21 | -9 | -11 |
| 21 | -3 | -5 | -5 | 4 | 51 | -2 | -4 | -2 | 2 | -20 | -7 | 29 |
| 56 | -4 | -5 | 12 | 8 | 11 | -4 | -4 | -5 | -7 | -20 | -8 | -10 |
| 48 | -7 | -6 | 4 | 9 | 49 | -5 | -6 | 55 | 4 | -12 | -8 | -5 |
| 63 | -7 | -4 | 15 | 7 | 27 | -3 | 1 | -4 | -7 | -21 | -9 | 3 |

*clones 56, 63, and 46 also demonstrate proliferative reactivity

Specificities indicated within parenthesis have not been tested but are as indicated based on the phenotyping data.

TABLE II Dissection of Determinants Associated with Different DR Dimers
Anti-DR4/Dw4/DQw3 Priming Combination

| Clones | Anti-DR mAb | | | | | | Anti-DRw53 mAb | | | Anti-DQ mAb | | |
|--------|--------------|------------|------------|------------|------------|-----------|----------------|------------|-----------|-------------|-----|-----------|
| | L243 | | | Hu4 | | | PL3 | | | Tu22 | | |
| | 80** | 400 | 4000 | 80 | 400 | 4000 | 80 | 400 | 4000 | 80 | 400 | 4000 |
| 15 | <u>113</u> * | <u>104</u> | <u>60</u> | <u>121</u> | <u>98</u> | <u>54</u> | NT | | | 14 | 25 | 31 |
| 37 | <u>121</u> | <u>129</u> | <u>121</u> | <u>111</u> | <u>79</u> | <u>57</u> | NT | | | 43 | 32 | <u>67</u> |
| 48 | <u>116</u> | <u>106</u> | <u>66</u> | <u>91</u> | <u>81</u> | 6 | 29 | -29 | -43 | -3 | 9 | 3 |
| 67 | <u>111</u> | <u>89</u> | 38 | <u>117</u> | <u>109</u> | <u>57</u> | 24 | 17 | 24 | -13 | -11 | 2 |
| 63 | <u>97</u> | 32 | 38 | <u>145</u> | <u>104</u> | 31 | -25 | -150 | 0 | 38 | 45 | <u>62</u> |
| 33 | <u>71</u> | 20 | 21 | <u>71</u> | 29 | 17 | -8 | -10 | 12 | 8 | 29 | 32 |
| 56 | <u>100</u> | <u>97</u> | 33 | | NT | | NT | | | NT | | |
| 45 | <u>100</u> | <u>100</u> | <u>100</u> | | NT | | NT | | | NT | | |
| 44 | <u>97</u> | <u>100</u> | <u>88</u> | | NT | | NT | | | NT | | |
| 21 | 7 | 8 | 14 | 20 | 2 | 10 | <u>101</u> | <u>104</u> | <u>76</u> | 14 | 5 | 29 |

* results expressed as % inhibition
value > 50% are underscored

NT = not tested

** reciprocal mAb dilutions

TABLE III Cytolytic Clones - Anti DR2/Dw2 Priming*

| | Targets | | | | | | | | | | | | | | | | | |
|---------|---------|------|------|------|------|-------|------|-------|------|------|------|-------|-------|-------|------|-------|------|------|
| | S1 | S2 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 |
| DR | 2,3 | 2,3 | 2,2 | 2,2 | 2,2 | 2,2 | 2,2 | 2,2 | 6,6 | 1,1 | 4,4 | 4,4 | 4,4 | 4,4 | 3,3 | 3,3 | 7,7 | 5,5 |
| Dw | 2,3 | 2,3 | 2,2 | 2,2 | 2,2 | 12,12 | FJ0 | LD-5a | 6,6 | 1,1 | 4,4 | 10,10 | 14,14 | 13,13 | 3,3 | 3,3 | 7,7 | 5,5 |
| DQ | 1,2 | 1,2 | 1 | 1 | NT | 1 | 1 | 3 | 1 | 1 | 3 | 3 | 3 | NT | NT | 2 | 2 | 3 |
| DP | 4,6 | 4 | 4,5 | 2,5 | NT | NT | NT | NT | 2,4 | 3,4 | 6,2 | 4 | 6,3 | NT | 1,3 | 3,4 | 4 | 4 |
| clone # | | | | | | | | | | | | | | | | | | |
| 3-89 | 19.1 | 38.3 | 5.2 | 23.3 | 41.4 | 7.8 | 1.3 | -2.8 | -7.8 | -7.5 | 2.4 | -1 | -7 | .1 | 6.4 | -16.5 | -1.2 | .2 |
| 3-17 | 23.8 | 25.5 | 19.4 | 28.7 | 29.0 | 3.5 | 1.9 | -2.8 | -3.6 | -8.0 | 3.6 | -6 | -9 | -7 | 4.2 | -19.1 | 1.7 | 2.9 |
| 3-19 | 14.8 | 27.9 | 13.6 | 40.1 | 54.6 | 4.3 | .2 | -2.0 | -1.8 | -5.0 | 7.4 | -1 | -5 | -1.7 | 4.9 | -16.9 | .4 | -1 |
| 1-12 | 27.7 | 43.5 | 35.1 | 54.0 | 40.4 | 19.8 | -5 | -6 | -5.5 | 2.0 | -9 | -1.4 | -2.1 | -2.7 | -6 | -17.3 | -3.5 | -7 |
| 3-84 | 11.1 | 21.5 | 13.8 | 43.5 | 40.4 | 30.4 | 4.1 | -2.6 | -6.9 | -4.9 | 3.3 | -2 | -5 | -1.5 | 1.4 | -16.3 | -1.2 | 4.5 |
| 3-91 | 10.5 | 6.3 | 14.4 | 13.5 | 19.0 | 17.7 | 5.3 | 4.9 | -8.0 | -6.7 | 7.2 | -1.1 | -1.3 | -2.4 | 1.7 | -19.3 | -6 | 1.5 |
| 3-29 | 26.8 | 27.0 | 21.6 | 40.9 | 30.7 | 29.2 | 46.6 | 42.8 | -8.3 | -7.1 | 8.1 | -7 | -2.8 | -4.2 | 12.5 | -16.3 | -2.0 | -1.2 |
| 1-17 | 11.2 | 20.1 | 22.4 | 20.0 | 24.1 | .5 | 4.7 | -3.1 | 51.0 | 26.2 | .7 | -7 | -2.0 | -2.9 | -6 | -17.1 | -1.3 | -6 |
| 3-27 | 27.2 | 44.9 | 17.6 | 53.1 | 49.8 | 35.9 | 17.7 | -1.3 | 46.9 | -4.8 | 4.4 | 51.0 | -2 | -1.3 | 1.8 | -15.3 | 2.0 | 3.9 |
| 1-109 | 14.6 | 56.7 | 33.6 | 55.0 | 44.0 | 8.8 | 16.1 | 44.8 | 12.6 | -8.2 | 14.3 | 37.4 | -3.0 | -3.0 | 5.6 | -18.2 | 22.9 | 4.3 |

*clone 3-19, 1-84, 3-91, 3-29, 3-27, 1-109 also demonstrated strong proliferative reactivity (>10,000 cpm) and clones

3-89, 3-17, and 1-17 demonstrated weaker proliferative reactivity

TABLE IV Dissection of Cloned Cytolytic T Cell Reactivity with Monoclonal Antibodies
Anti-DR2/Dw2/DQw1 Priming Combination

| Clones | Anti-DR mAb | | | | Anti-DQw1 mAb | | | | Anti-Class I | | | |
|--------|-------------|-----|------|-----|---------------|------|-----|-----|--------------|-----|-----|------|
| | Hu4 | | | | S 3/4 | | | | FA | | | |
| | 80 | 400 | 4000 | 80 | 400 | 4000 | 80 | 400 | 4000 | 80 | 400 | 4000 |
| 3-19 | 97* | 67 | 24 | NT | 12 | 6 | 15 | 12 | 21 | NT | NT | NT |
| 3-29 | 108 | 62 | 0 | NT | 15 | 23 | 8 | 31 | 8 | 46 | NT | NT |
| 3-27 | 89 | 53 | 42 | 92 | 47 | 37 | 53 | 47 | 26 | 32 | 27 | 64 |
| | | | | | | | | | | | 18 | 20 |
| 3-89 | -8 | 10 | 6 | -52 | -34 | 0 | 3 | 115 | 100 | 64 | 49 | 26 |
| | | | | | | | | | | | | 21 |
| 3-17 | -69 | -50 | 50 | NT | 138 | 106 | 106 | 113 | 81 | 50 | NT | NT |
| 1-17 | -57 | -86 | -29 | NT | 157 | 200 | 200 | 143 | 143 | 114 | NT | NT |
| 1-12 | 32 | -4 | 20 | -34 | -42 | -49 | 57 | 24 | 20 | 8 | 24 | 32 |
| | | | | | | | | | | | 40 | 20 |
| 1-109 | 46 | 15 | 31 | -69 | -56 | -100 | 81 | -8 | 8 | -8 | 15 | 23 |
| | | | | | | | | | | | 46 | 19 |
| | | | | | | | | | | | 64 | -19 |

* results expressed as % inhibition

values $\geq 50\%$ are underscored

NT = not tested

** reciprocal mAb dilution

TABLE V HLA-DR and DQ Determinants Comprising a "Dw Specificity"

| | | LCL target cells | | | | | | | | |
|-------------------|------|------------------|------------|------------|------------|------------|------------|------------|-----------|-----------|
| | | S | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| HLA | DR | <u>2,3</u> | <u>2,2</u> | <u>2,2</u> | <u>2,2</u> | <u>2,2</u> | <u>2,2</u> | <u>2,2</u> | 6,6 | 1,1 |
| | Dw | <u>2,3</u> | <u>2,2</u> | <u>2,2</u> | <u>2,2</u> | 12,12 | FJO | LD-5a | 6,6 | 1,1 |
| | DQw | <u>1,2</u> | <u>NT</u> | <u>1</u> | <u>NT</u> | <u>1</u> | <u>1</u> | 3 | <u>1</u> | <u>1</u> |
| | DPw | 4,6 | 4,5 | 2,5 | NT | NT | NT | NT | 2,4 | 3,4 |
| | | <hr/> | | | | | | | | |
| Anti-DR Clones | 3-19 | <u>15</u> | <u>14</u> | <u>40</u> | <u>55</u> | 4 | 1 | -2 | -2 | -5 |
| | 3-29 | <u>27</u> | <u>22</u> | <u>41</u> | <u>31</u> | <u>29</u> | <u>47</u> | <u>43</u> | -8 | -7 |
| | 3-27 | <u>27</u> | <u>18</u> | <u>53</u> | <u>50</u> | <u>36</u> | <u>18</u> | -1 | <u>47</u> | -5 |
| | | <hr/> | | | | | | | | |
| Anti-DQ Clones | 3-89 | <u>19</u> | 5 | <u>23</u> | <u>41</u> | 8 | 1 | -3 | -8 | -8 |
| | 3-17 | <u>24</u> | <u>19</u> | <u>29</u> | <u>29</u> | 4 | 2 | -3 | -4 | -8 |
| | 1-17 | <u>11</u> | <u>22</u> | <u>29</u> | <u>24</u> | 1 | 5 | -3 | <u>51</u> | <u>26</u> |

TABLE VI

Proliferative Clones - Anti-DR/Dw4 Priming*

| | | Secondary Stimulators | | | | | | | | | |
|--------|----|-----------------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|--------------|-------------|
| | | S | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| HLA-DR | | <u>3,4</u> | <u>4,4</u> | <u>4,7</u> | <u>4,4</u> | <u>4,4</u> | <u>4,6</u> | <u>4,4</u> | <u>4,6</u> | <u>4,4</u> | <u>4,4</u> |
| | Dw | <u>3,4</u> | <u>4,4</u> | <u>4,7</u> | <u>4,4</u> | 13,4 | 14,6 | 14,14 | 14,6 | 14,14 | 10,10 |
| | DQ | <u>3</u> | <u>3</u> | <u>2,3</u> | <u>3</u> | <u>3</u> | <u>1,3</u> | <u>3</u> | <u>1,3</u> | <u>3</u> | <u>3</u> |
| | DP | 1 | 4 | 4 | 6 | 2,4 | 4 | 3,6 | 4 | 6,4 | 4 |
| Clones | 16 | <u>8958</u> | <u>26728</u> | 3616 | <u>14664</u> | <u>45312</u> | <u>37042</u> | <u>44756</u> | <u>58580</u> | <u>15786</u> | <u>9654</u> |
| | 56 | <u>21952</u> | <u>36942</u> | <u>12050</u> | <u>28858</u> | <u>27776</u> | 2344 | <u>27260</u> | <u>15450</u> | <u>25216</u> | 998 |
| | 63 | <u>4022</u> | <u>9232</u> | 1270 | 1928 | <u>4710</u> | 1000 | 634 | 348 | 100 | 346 |
| | 40 | <u>4244</u> | 1654 | 1732 | <u>3874</u> | 362 | 1740 | 106 | 116 | 1262 | 836 |
| | 41 | <u>5700</u> | <u>8588</u> | 2180 | <u>5656</u> | <u>7902</u> | 280 | <u>4350</u> | <u>3722</u> | 802 | 684 |
| | | Secondary Stimulators | | | | | | | | | |
| | | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | |
| HLA-DR | | <u>4,5</u> | <u>4,4</u> | 3,5 | 2,7 | 2,5 | 8 | 1,6 | 2,3 | 3,7 | |
| | Dw | 10,5 | 15,15 | 3 | 2,7 | 2 | 8 | 6 | 2,3 | 3,7 | |
| | DQ | <u>3</u> | - | <u>2,3</u> | 1,2,3, | <u>1,3</u> | <u>3</u> | 1 | 1,2 | 2 | |
| | DP | 4 | 5 | 2,4 | 4 | 4 | 4 | 1 | 1,2 | 4 | |
| Clones | 16 | <u>17762</u> | <u>22120</u> | 524 | 690 | 512 | 812 | 100 | 661 | 100 | |
| | 56 | 7730 | 1008 | 436 | 408 | 702 | 100 | 100 | 222 | 100 | |
| | 63 | 860 | 342 | 116 | 168 | 208 | 100 | 162 | 162 | 248 | |
| | 40 | <u>5562</u> | 2666 | <u>6436</u> | 2504 | <u>7136</u> | <u>5970</u> | 1826 | 1885 | 1782 | |
| | 41 | 1082 | <u>9588</u> | 498 | 1744 | <u>4370</u> | 478 | 149 | 100 | 196 | |

*clones 56 and 63 also demonstrated cytolytic reactivity

TABLE VII Proliferative Clones - Anti-DR2/Dw2 Priming*

| | | Secondary Stimulators | | | | | | | | |
|-------------|--|-----------------------|--------------|--------------|-------------|-------------|-------------|--------------|--------------|-------------|
| | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| HLA-DR | | <u>2,2</u> | <u>2,5</u> | <u>1,2</u> | <u>2,6</u> | <u>1,2</u> | <u>2</u> | <u>2,3</u> | <u>2,5</u> | <u>2</u> |
| Dw | | <u>2,2</u> | <u>2,5</u> | <u>1,2</u> | 6,MN2 | 1,MN2 | MN2 | 12,3 | 5,- | - |
| DQ | | <u>1</u> | <u>1</u> | <u>1</u> | <u>1</u> | <u>1</u> | <u>1</u> | <u>1,2</u> | NT | NT |
| DP | | <u>4,5</u> | <u>3</u> | <u>4</u> | NT | NT | <u>3,4</u> | - | NT | <u>2,4</u> |
| Clones 3-70 | | <u>5184</u> | <u>5860</u> | 1574 | 100 | 236 | 1052 | 576 | 1152 | 130 |
| 1-101 | | <u>22344</u> | <u>15732</u> | <u>12758</u> | 100 | 168 | 100 | 200 | <u>5082</u> | 580 |
| 1-84 | | <u>29572</u> | <u>17460</u> | <u>11586</u> | 1127 | 144 | <u>9808</u> | 812 | 135 | 162 |
| 3-22 | | <u>11616</u> | <u>14568</u> | <u>7926</u> | 696 | 1074 | 2572 | <u>7422</u> | <u>7006</u> | 100 |
| 3-29 | | <u>18454</u> | <u>28166</u> | <u>14048</u> | 422 | 3312 | 3470 | <u>14750</u> | <u>22674</u> | 266 |
| 1-109 | | <u>9422</u> | <u>28080</u> | <u>8226</u> | <u>6126</u> | <u>5642</u> | <u>9840</u> | <u>6798</u> | <u>28814</u> | <u>7790</u> |
| | | Secondary Stimulators | | | | | | | | |
| | | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| HLA-DR | | <u>2,4</u> | 4,4 | 4,4 | 1,1 | 6,6 | 4,5 | 3,3 | 3,4 | 7,8 |
| Dw | | 14,- | 4,4 | 14,14 | 1,1 | 6,6 | 13,5 | 3,3 | 3,4 | 7,8 |
| DQ | | <u>1,3</u> | 3 | 3 | <u>1</u> | <u>1</u> | 3 | 2 | 2,3 | 2 |
| DP | | NT | <u>6</u> | <u>6,3</u> | 3,4 | 2,4 | 4 | 1,3 | 3,4 | 4 |
| Clones 3-70 | | 634 | 310 | 248 | 590 | 1276 | 640 | 280 | 690 | 1004 |
| 1-101 | | 1712 | 343 | 100 | 116 | 448 | 1420 | 546 | 174 | 100 |
| 1-84 | | 100 | 266 | 432 | 100 | 234 | 434 | 218 | 273 | 196 |
| 3-22 | | <u>6704</u> | 100 | 100 | 210 | 250 | <u>4950</u> | 634 | 100 | 131 |
| 3-29 | | <u>13674</u> | 230 | 143 | 150 | 100 | <u>4708</u> | 100 | 100 | 120 |
| 1-109 | | <u>8608</u> | 722 | 100 | 171 | <u>8326</u> | <u>5908</u> | 112 | 246 | 1250 |

*clones 3-22, 3-29 and 1-109 also demonstrated cytolytic reactivity

TABLE VIII Proliferative LDA Reagents (generated from LDA of 5 cells per well)
Anti-DR/Dw2 Priming

| | | Secondary Stimulators | | | | | | | | |
|---------|------|-----------------------|--------------|--------------|-------------|----------|------|--------------|--------------|------|
| | | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
| HLA-DR | | 2,2 | 2,5 | 1,2 | 2,6 | 1,2 | 2 | 2,3 | 2,5 | 2 |
| Dw | | 2,2 | 2,5 | 1,2 | 6,MN2 | 1,MN2 | MN2 | 12,3 | 5,- | - |
| DQ | | 1 | 1 | 1 | 1 | 1 | 1 | 1,2 | NT | NT |
| DP | | 4,5 | 3 | 4 | NT | NT | 3,4 | - | NT | 2,4 |
| Reagent | 596 | <u>6246</u> | <u>7856</u> | <u>7106</u> | 186 | 100 | 226 | 314 | 458 | 1280 |
| | 5178 | <u>18565</u> | <u>17346</u> | <u>21498</u> | 538 | 172 | 408 | 1692 | 1606 | 2224 |
| | 5186 | <u>8918</u> | <u>10840</u> | 3570 | 318 | 474 | 140 | 1032 | 830 | 698 |
| | 5210 | <u>4065</u> | <u>4930</u> | <u>6162</u> | 362 | 132 | 245 | 738 | 576 | 166 |
| | 5125 | <u>4216</u> | <u>13648</u> | <u>6632</u> | 390 | 272 | 310 | <u>5226</u> | 278 | 210 |
| | 5181 | <u>13462</u> | <u>6456</u> | <u>8518</u> | <u>3944</u> | 700 | 1100 | <u>15204</u> | <u>10568</u> | 441 |
| | | Secondary Stimulators | | | | | | | | |
| | | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| HLA-DR | | <u>2,4</u> | 4,4 | 4,4 | 1,1 | 6,6 | 4,5 | 3,3 | 3,4 | 7,8 |
| Dw | | 14 | 4,4 | 14,14 | 1,1 | 6,6 | 13,5 | 3,3 | 3,4 | 7,8 |
| DQ | | <u>1,3</u> | 3 | 3 | <u>1</u> | <u>1</u> | 3 | 2 | 2,3 | 2 |
| DP | | NT | <u>6</u> | <u>6,3</u> | 3,4 | 2,4 | 4 | 1,3 | 3,4 | 4 |
| Reagent | 596 | 100 | 138 | 100 | 126 | 111 | 100 | 100 | 100 | 364 |
| | 5178 | 346 | 1318 | 1244 | 250 | 1510 | 964 | 582 | 940 | 1616 |
| | 5186 | 770 | 666 | 100 | 238 | 156 | 142 | 100 | 171 | 252 |
| | 5210 | 294 | 1288 | 450 | 139 | 750 | 152 | 302 | 100 | 166 |
| | 5125 | 1116 | 268 | 180 | 148 | 280 | 100 | 336 | 568 | 366 |
| | 5181 | <u>11200</u> | 1170 | 773 | 170 | 254 | 178 | 699 | 628 | 1768 |

END

FILMED

11-85

DTIC